Med. praxi. 2016;13(3):120-123 | DOI: 10.36290/med.2016.026

Hypertension from the perspective of the less common situations

MUDr. Zuzana Krátká, Ph.D., MUDr. Ondřej Petrák, Ph.D.
Centrum pro výzkum, diagnostiku a léčbu arteriální hypertenze, 3. interní klinika VFN a 1. LF UK, Praha

This paper is focused on some less common forms of arterial hypertension, where early detection and appropriate treatment can

significantly affect the prognosis of the patient. The first part of the article is about pharmacoresistant arterial hypertension, its

etiology, diagnostics, and especially about the treatment. The second part is devoted to secondary causes of arterial hypertension,

with emphasis on some typical clinical and laboratory findings.

Keywords: arterial hypertension, secondary hypertension, pharmacoresistant hypertension

Published: July 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Krátká Z, Petrák O. Hypertension from the perspective of the less common situations. Med. praxi. 2016;13(3):120-123. doi: 10.36290/med.2016.026.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. The Lancet 2005; 365(9455): 217-223. Go to original source... Go to PubMed...
    2. Soucek M, Kára T. Klinická patofyziologie hypertenze. Praha: Grada 2002.
    3. Widimsky? J. Hypertenze. 3. rozšířené a přepracované vyd., Praha: Triton 2008.
    4. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31(7): 1281-1357. Go to original source... Go to PubMed...
    5. Widimský J jr. Rezistentní hypertenze: stručný přehled rizikových faktorů. In: Arteriální hypertenze - současné klinické trendy X. Triton Praha 2012.
    6. Mazzaglia G, Mantovani LG, Sturkenboom MCJM, et al. Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. J Hypertens 2005; 23(11): 2093-2100. Go to original source...
    7. Strauch B, Petrák O, Zelinka T, et al. Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. J Hypertens 2013; 31(12): 2455-2461. Go to original source...
    8. Brown MA, Buddle ML, Martin A. Is resistant hypertension really resistant? Am J Hypertens 2001; 14(12): 1263-1269. Go to original source...
    9. Hermida RC, Ayala DE, Calvo C et al. Effects of time of day of treatment on ambulatory blood pressure pattern of patients with resistant hypertension. Hypertension 2005; 46(4): 1053-1059. Go to original source... Go to PubMed...
    10. Dolan E, Stanton A, Atkins N, et al. Determinants of white-coat hypertension. Blood Press Monit 2004; 9(6): 307-309. Go to original source... Go to PubMed...
    11. Widimsky? J. Sekundární hypertenze. Praha: Triton 2003.
    12. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51(6): 1403-1419. Go to original source... Go to PubMed...
    13. Filipovský J, Widimský J jr, Ceral J, et al. Diagnostické a léčebné postupy u arteriální hypertenze - verze 2012. Doporučení České společnosti pro hypertenzi. Hypertenze Kardiovaskulární Prevence 2012; 3: 1-16.
    14. ONTARGET Investigators, Yusuf S, Teo KK, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 10 2008; 358(15): 1547-1559. Go to original source...
    15. Fried LF, Emanuele N, Zhang JH, et al. Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy. N Engl J Med. 14 2013; 369(20): 1892-1903. Go to original source...
    16. Alvarez-Alvarez B, Abad-Cardiel M, Fernandez-Cruz A, Martell-Claros N. Management of resistant arterial hypertension: role of spironolactone versus double blockade of the renin-angiotensin-aldosterone system. J Hypertens 2010; 28(11): 2329-2335. Go to original source...
    17. Chapman N, Chang CL, Dahlöf B, et al. Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial. Circulation 2008; 118(1): 42-48. Go to original source...
    18. Black HR, Keck M, Meredith P, Bullen K, Quinn S, Koren A. Controlled-release doxazosin as combination therapy in hypertension: the GATES study. J Clin Hypertens Greenwich Conn 2006; 8(3): 159-166; quiz 167-168. Go to original source... Go to PubMed...
    19. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117(25): 510-526. Go to original source...
    20. Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf) 2007; 66(5): 607-618. Go to original source... Go to PubMed...
    21. Štrauch B, Zelinka T, Hampf M. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens 2003; 17(5): 349-352. Go to original source... Go to PubMed...
    22. Milliez P, Girerd X, Plouin P, et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45(8): 1243-1248. Go to original source...
    23. Rossi GP, Bernini G, Desideri G, et al. Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension 2006; 48(2): 232-238. Go to original source...
    24. Matsumura K, Fujii K, Oniki H, et al. Role of aldosterone in left ventricular hypertrophy in hypertension. Am J Hypertens 2006; 19(1): 13-18. Go to original source...
    25. Fallo F, Veglio F, Bertello C, et al. Prevalence and Characteristics of the Metabolic Syndrome in Primary Aldosteronism. J Clin Endocrinol Metab 2006; 91(2): 454-459. Go to original source...
    26. Strauch B, Petrák O, Wichterle D, et al. Increased arterial wall stiffness in primary aldosteronism in comparison with essential hypertension. Am J Hypertens 2006; 19(9): 909-914. Go to original source...
    27. Holaj R, Zelinka T, Wichterle D, et al. Increased intima-media thickness of the common carotid artery in primary aldosteronism in comparison with essential hypertension. J Hypertens 2007; 25(7): 1451-1457. Go to original source...
    28. Widimsky? J jr, Widimsky? J. Hypertenze. Praha: Triton 2014.
    29. Young WF Jr, Klee GG. Primary aldosteronism. Diagnostic evaluation. Endocrinol Metab Clin North Am 1988; 17(2): 367-395. Go to original source... Go to PubMed...
    30. Zelinka T, Strauch B, Pecen L, Widimský J. jr. Diurnal blood pressure variation in pheochromocytoma, primary aldosteronism and Cushing's syndrome. J Hum Hypertens 2004; 18(2): 107-111. Go to original source... Go to PubMed...
    31. Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93(9): 3266-3281. Go to original source...
    32. Celen O, O'Brien MJ, Melby JC, Beazley RM. Factors influencing outcome of surgery for primary aldosteronism. Arch Surg Chic Ill 1960 1996; 131(6): 646-650. Go to original source... Go to PubMed...
    33. Lumachi F, Ermani M, Basso SMM, et al. Long-term results of adrenalectomy in patients with aldosterone-producing adenomas: multivariate analysis of factors affecting unresolved hypertension and review of the literature. Am Surg 2005; 71(10): 864-869. Go to original source... Go to PubMed...
    34. Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing's syndrome. The Lancet 2006; 367(9522): 1605-1617. Go to original source... Go to PubMed...
    35. Vyskočilová J, Šonka K. Porucha dýchání ve spánku. Interní Medicína Praxi 2005(11).
    36. Somers VK, White DP, Amin R, et al. Sleep Apnea and Cardiovascular Disease: An American Heart Association/American College of Cardiology Foundation Scientific Statement From the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing In Collaboration With the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health). Circulation 2008; 118(10): 1080-1111. Go to original source...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.